Favorable safety profile and effective biochemical control in 52-week trial Significant improvement of acromegaly symptoms vs. standard of care at baseline Improved patient reported treatment ...
October 13, 2010 (Liege, Belgium) — In patients with treatment-resistant, active acromegaly, normalizing insulin-like growth factor 1 (IGF-1) levels leads to a marked reduction in cardiovascular risk, ...
Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...
Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...
Please provide your email address to receive an email when new articles are posted on . An AI model correctly identified 22 of 31 adults as having acromegaly strictly based on voice recordings. The ...
MedPage Today on MSN
Heart risks after GLP-1 hiatus; TED drug success; top diabetes researcher dies
News and commentary from the endocrinology world ...
Crinetics Pharmaceuticals announced that it will present two abstracts at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2025, highlighting the investigational treatment ...
A personalized treatment protocol was more effective for management of acromegaly -- also known as gigantism -- than the usual trial-and-error approach, the ...
IGF-1 levels remained stable at week 96 for PATHFNDR-1 patients switched to oral palsonify. Daily symptom flares dropped from over 30% on injectables to 6.2% with palsonify in PATHFNDR-1. Get a Year ...
May 29, 2012 (Florence, Italy) — In patients with acromegaly, long-acting-release (LAR) pasireotide (SOM230, Novartis) was more effective than octreotide LAR (Sandostatin, Novartis) at inducing ...
Application supported by comprehensive clinical program, including two positive Phase 3 trials evaluating once-daily oral paltusotine in acromegalySAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- ...
The dynamics of the acromegaly market are anticipated to change due to extensive R&D, the entry of novel therapies such as Debio 4126 (Debiopharm International SA), ALXN2420 (AstraZeneca), MAR002 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results